Filtered By:
Vaccination: Meningitis Vaccine

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 2865 results found since Jan 2013.

Prevention of serogroup B meningococcal disease using a four-component vaccine.
CONCLUSIONS: The 4CMenB vaccine is the only strategy currently available to prevent meningococcal disease caused by serogroup B. PMID: 24119683 [PubMed - as supplied by publisher]
Source: Anales de Pediatria - October 9, 2013 Category: Pediatrics Authors: Gil A, Barranco D, Batalla J, Bayas JM, Campins M, Gorrotxategi Gorrotxategi P, Lluch J, Martinón-Torres F, Mellado MJ, Moreno-Pérez D, Uriel B, Vázquez JA Tags: An Pediatr (Barc) Source Type: research

Effectiveness of 2+1 PCV7 vaccination schedules in children under 2 years: A meta-analysis of impact studies.
Abstract Although a case control study suggested high effectiveness of the 2+1 PCV-7 vaccination, schedule against invasive pneumococcal disease (IPD) in children the results of impact studies in, different countries yield considerable differences in the magnitude of the effects. A systematic, literature review was conducted to identify all relevant studies on IPD incidence reduction after onset, of PCV7 vaccination programmes in children younger than 2 years of age given in the 2+1 schedule. The incidence rate ratio between IPI incidences for vaccine serotypes before and after beginning of the, vaccination progra...
Source: Vaccine - October 18, 2013 Category: Allergy & Immunology Authors: Schönberger K, Kirchgässner K, Riedel C, von Kries R Tags: Vaccine Source Type: research

Vaccines for measles, mumps and rubella in children
Abstract BackgroundMumps, measles and rubella (MMR) are serious diseases that can lead to potentially fatal illness, disability and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness. ObjectivesTo assess the effectiveness and adverse effects associated with the MMR vaccine in children up to 15 years of age. Search methodsFor this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 2), which includes the...
Source: Evidence-Based Child Health: A Cochrane Review Journal - November 20, 2013 Category: Pediatrics Authors: Vittorio Demicheli, Alessandro Rivetti, Maria Grazia Debalini, Carlo Di Pietrantonj Tags: Intervention Review Source Type: research

MenHibrix: A New Combination Meningococcal Vaccine for Infants and Toddlers.
CONCLUSIONS: Hib-MenCY-TT has been demonstrated to be a safe and immunogenic vaccination for prevention of disease caused by N meningitidis serogroups C and Y and H influenzae type b in healthy infants and toddlers. Currently, the ACIP recommends the use of Hib-MenCY-TT specifically in high-risk infants aged 6 weeks to 18 months. Hib-MenCY-TT provides the first therapeutic option for vaccination of infants as young as 6 weeks of age who are at increased risk for meningococcal disease. PMID: 24353263 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - December 18, 2013 Category: Drugs & Pharmacology Authors: Hale SF, Camaione L, Lomaestro BM Tags: Ann Pharmacother Source Type: research

Vaccination of Older Adults with Dementia Against Respiratory Infections.
Abstract People with dementia are at a greater risk of complications from respiratory infections therefore can benefit from vaccinations against influenza, pneumococcal disease and pertussis. This review aimed to evaluate the uptake and impact of vaccination in older adults with dementia against respiratory infections and identify knowledge gaps. Key databases were explored, search results were assessed, relevant studies identified, and data were synthesised and summarised. Most available data suggest that older adults with dementia are less likely to receive influenza or pneumococcal vaccine while a few studies i...
Source: Infectious Disorders Drug Targets - July 13, 2014 Category: Infectious Diseases Authors: Ridda I, Dastouri F, King C, Yin JK, Tashani M, Rashid H Tags: Infect Disord Drug Targets Source Type: research

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: Herpes zoster vaccine is effective in preventing herpes zoster disease. Although vaccine benefits are larger in the younger age group (60 to 69 years), this is also the age group with more adverse events. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity. PMID: 25055074 [PubMed - as supplied by publisher]
Source: Sao Paulo Medical Journal - July 24, 2014 Category: Journals (General) Authors: Gagliardi AM, Silva BN, Torloni MR, Soares BG Tags: Sao Paulo Med J Source Type: research

Relationships Between Clinico-Epidemiological Patterns of Invasive Meningococcal Infections and Complement Deficiencies in French South Pacific Islands (New Caledonia)
Conclusions A high prevalence of C-deficiency in the Melanesian population may explain epidemiological and clinical features of IMD in NC. Our results imply an adaptation of meningococcal vaccine strategies in NC.
Source: Journal of Clinical Immunology - October 29, 2014 Category: Allergy & Immunology Source Type: research

Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.
Source: The Journal of Infection in Developing Countries - December 15, 2014 Category: Infectious Diseases Source Type: research

Pneumococcal vaccination during pregnancy for preventing infant infection.
CONCLUSIONS: There is insufficient evidence to assess whether pneumococcal vaccination during pregnancy could reduce infant infections. PMID: 25613573 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - January 23, 2015 Category: Journals (General) Authors: Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, Lumbiganon P, Tolosa JE Tags: Cochrane Database Syst Rev Source Type: research

Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies
Conclusion PV is associated with decreased risk of cardiovascular events and mortality. This protective effect increases at older age and in high cardiovascular risk subjects and decreases as the time elapses from PV. PV decreases the risk of MI and cerebrovascular events in the elderly.
Source: European Journal of Preventive Cardiology - August 10, 2015 Category: Cardiology Authors: Vlachopoulos, C. V., Terentes-Printzios, D. G., Aznaouridis, K. A., Pietri, P. G., Stefanadis, C. I. Tags: Original scientific paper Source Type: research

Reccurrent invasive pneumococcal disease in children host factors and vaccination response.
Authors: Ingels HA Abstract Streptococcus pneumoniae is still a leading cause of septicaemia, pneumonia and meningitis in young children world-wide with over half a million children dying annually from pneumococcal disease.  Some children are prone to repeated episodes of invasive pneumococcal disease (IPD) because of an underlying predisposing disease. Recurrent IPD (rIPD) is a rarity and published reports on rIPD are limited by having few children included, selected groups of patients or short follow-up periods. Deficiencies in the innate or adaptive immune system have been described in children with rIPD, but t...
Source: Danish Medical Journal - December 12, 2015 Category: Journals (General) Tags: Dan Med J Source Type: research

A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.
CONCLUSIONS: Our meta-analysis did not show any safety concerns in clinical trials of the newly adjuvanted vaccines in children ≤10 years of age. An unexplained increase of meningitis in one Phase III AS01-adjuvanted malaria trial and the link between narcolepsy and the AS03-adjuvanted pandemic vaccine illustrate that continued safety monitoring is warranted. PMID: 26740250 [PubMed - as supplied by publisher]
Source: Vaccine - December 28, 2015 Category: Allergy & Immunology Authors: Stassijns J, Bollaerts K, Baay M, Verstraeten T Tags: Vaccine Source Type: research

Global Burden of Neonatal Invasive Pneumococcal Disease: A Systematic Review and Meta-analysis
Conclusions: Pneumococcus was a recognized pathogen among neonates in all development regions of the world. The burden of neonatal IPD, particularly in the least-developed UN country stratum, requires substantial further evaluation.
Source: The Pediatric Infectious Disease Journal - January 12, 2016 Category: Infectious Diseases Tags: Original Studies Source Type: research

Methods and challenges for the health impact assessment of vaccination programs in Latin America
CONCLUSIONS Over the last years, a significant number of health impact assessments of pneumococcal and rotavirus vaccination programs have been conducted in Latin America and the Caribbean. These studies were carried out few years after the programs were implemented, meet the basic methodological requirements and suggest positive health impact. Future assessments should consider methodological issues and challenges arisen in these first studies conducted in the region. RESUMO OBJETIVO Descrever métodos e desafios enfrentados na avaliação do impacto de programas de vacinação, com foco nas vacinas pneumocócica conjugad...
Source: Revista de Saude Publica - January 15, 2016 Category: Global & Universal Source Type: research